Bluejay IPO Presentation Deck
Symphony Product Pipeline Targets Multi-Billion Dollar Markets*
Plan to expand the testing menu to include other well-validated critical care biomarkers
Product Pipeline
Commercial Rights
Symphony ™M IL-6
Sepsis Triage
Bluejay Diagnostics
SymphonyTM hsTNT/I
Triage
Bluejay Diagnostics and
Toray Industries
SymphonyTM NT-
proBNP Triage
Bluejay Diagnostics and
Toray Industries
Research
bluejay
Development
*Source: Bluejay Diagnostics market research
>>
Clinical Testing
>>
Regulatory
Estimated Market
Opportunity*
Hospitals: $925M +
LTAC: $2-3B
Ongoing investment in Symphony System to improve user interface and support user adoption
New Tests Will Follow the IL-6 Development Pathway
Hospitals: $3.6B
Copyright ©2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 10View entire presentation